Michael Blum
No más puestos en curso
Fortuna: 14 770 $ al 30/04/2024
Historial de carrera de Michael Blum
Antiguos cargos conocidos de Michael Blum.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2015 | 01/11/2017 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2013 | 01/04/2015 |
| Q32 BIO INC. | Corporate Officer/Principal | 01/11/2017 | - |
Formación de Michael Blum.
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
| Babson College | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 6 |
Operativa
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Blum
- Experiencia